Synthetic Immunotherapy: Programming Immune Cells with Novel and Sophisticated Logic Capabilities

Area of Science:

• Immunology
• Biotechnology
• Synthetic Biology

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for cancer treatment.
• Current CAR T cell designs have limitations, including off-target toxicity and cytokine release syndrome.
• Improvements are needed to enhance the safety and efficacy of CAR T cell therapies.

Purpose of the Study:

• To review the logic capabilities and limitations of current CAR T cell therapies.
• To explore how synthetic biology can overcome these limitations.
• To introduce the concept of "synthetic immunotherapy" enabled by engineered T cells.

Main Methods:

• Review of existing CAR T cell technology and its limitations.
• Discussion of synthetic biology tools and their application to CAR T cell engineering.
• Analysis of how synthetic biology enables advanced logic in T cells.

Main Results:

• Current CAR T cells have simple logic, leading to toxicity issues.
• Synthetic biology allows for modular receptors with customizable sensors and outputs.
• Engineered T cells demonstrate enhanced capabilities like multi-antigen discrimination and improved persistence.

Conclusions:

• Synthetic biology offers a powerful solution to enhance CAR T cell therapy.
• Engineered T cells pave the way for a new era of "synthetic immunotherapy."
• Further development of synthetic immunotherapy holds significant potential for cancer treatment.